Every 10-Q that Hyperfine, Inc. (HYPR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow HYPR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HYPR filings page.
Hyperfine, Inc. reported higher revenue but continued losses for the quarter ended June 30, 2026. Total revenue was $3,904 (thousands), up from $2,696 (thousands) a year earlier, driven by increased Swoop® portable MRI device and service sales and higher average selling prices.
Gross profit improved to $1,980 (thousands), while operating expenses declined modestly to $10,449 (thousands), narrowing the operating loss to $8,469 (thousands). Net loss was $9,298 (thousands), similar to the prior-year quarter, with new interest expense and higher warrant-liability fair-value losses offsetting operating improvements. For the first half of 2026, revenue reached $7,807 (thousands) and net loss was $17,921 (thousands). Hyperfine sold 12 Swoop® systems in the quarter and 22 year-to-date. Cash, cash equivalents and restricted cash increased to $44,764 (thousands), supported by a new $15,000 (thousands) term loan and at-the-market equity sales, though long-term debt rose to $13,235 (thousands). Management expects existing capital and anticipated revenue to fund operations for at least twelve months while acknowledging a need to grow revenue or raise additional financing over the longer term.
Hyperfine, Inc. reported strong top-line growth but continued losses for the three months ended March 31, 2026. Revenue rose to $3.9 million from $2.1 million, driven mainly by higher Swoop portable MRI device sales and a higher average selling price. Gross profit more than doubled to $2.0 million, while operating expenses fell to $10.5 million, narrowing the net loss to $8.6 million from $9.4 million.
Cash, cash equivalents and restricted cash were $41.3 million at quarter end, helped by a new $15 million draw under a senior secured term loan facility that can provide up to $40 million in total. Operating activities used $9.0 million of cash. Management believes current capital, including this financing, will fund operations for at least twelve months, but ongoing losses and limited revenue mean the business still depends on future capital raises. The company continued to secure important regulatory milestones for its AI-powered Swoop system in the United States, Europe, the United Kingdom and India, supporting its strategy to expand portable MRI adoption globally.
Hyperfine, Inc. filed its Q3 2025 report, showing modest revenue softness and continued investment in product and market expansion. Revenue was $3.4M for the quarter, down slightly from $3.6M a year ago, with gross margin of $1.8M. Net loss was $11.0M versus $10.3M last year, and operating expenses totaled $10.8M.
Cash and cash equivalents were $21.6M as of September 30, 2025, compared with $37.6M at year-end 2024. Operating cash outflow for the first nine months was $22.7M. During 2025, the company raised capital via a February registered direct offering ($6.0M gross) with accompanying warrants and an at-the-market program. After quarter-end, it completed an underwritten public offering totaling $20.1M gross (approximately $18.4M net).
Product development advanced with FDA 510(k) clearance in May 2025 for the Optive AI software and next‑generation Swoop system, and August 2025 CE Mark/UKCA approvals. Shares outstanding were 82,113,369 Class A and 15,055,288 Class B as of November 3, 2025.